Executive Team

Spencer Malouf

Michael Gaisford MBA

President and CEO, Director

Over 15 years experience leading teams in marketing, strategy, and product management. Prior to Intera, Michael was Director of Marketing for Stratasys Healthcare Solutions, he oversaw global marketing programs across medical and dental markets. At Boston Scientific, he led the productivity office, managed product marketing in the Electrophysiology division, and supported commercial strategic initiatives in neuromodulation, urology and endoscopy groups. Michael previously worked at Genentech, CVS/Pharmacy, and McKinsey & Company. He holds an MBA from the Tuck School of Business at Dartmouth and BS from Stanford University.
Spencer Malouf

Spencer Malouf

Vice President of Sales

Over 25 years of medical and surgical device, sales, marketing, and sales management. Prior to Intera Oncology Spencer led a distributorship that specialized in Neuromodulation and Oncology (Hepatic Arterial Infusion) sales for Codman, Johnson & Johnson. His success in building and growing HAI programs in major cancer centers across the nation has given him the knowledge, sales leadership and strategic relationships that he brings to Intera Oncology. Spencer also trained and managed a national sales team for Innovative Pump Solutions, growing it from a new company to one of the top intrathecal compounding pharmacies in the nation in five years. He graduated from Texas Tech University with a BA and immediately went to work in the medical sales field.
Spencer Malouf

Sheila Hemeon Heyer, JD, RAC

Regulatory Affairs - Heyer Regulatory Solutions LLC

Intera Oncology has engaged Heyer Regulatory Solutions LLC (HRS) for Regulatory Affairs and Regulatory Compliance. Founded in 2010, HRS provides premarket regulatory strategy and submissions as well as postmarket regulatory compliance services to the global medical device industry. Founder and President Sheila Hemeon-Heyer has over 30 years experience beginning at FDA where she was a Scientific Reviewer in the CDRH Office of Device Evaluation, as Director of Regulatory Services for Medical Device Consultants, Inc. (MDCI), and as Vice President, Global Regulatory Affairs for Boston Scientific Corporation. She holds a B.S. in Biomedical Engineering from Boston University, an M.S. in Biomechanics from the University of Massachusetts at Amherst, a J.D. from Western New England College School of Law, is US and EU Regulatory Affairs Certified and is a Fellow of the Regulatory Affairs Professional Society.
Sarah Lapp

Sarah Lapp

Associate Director of Quality

Sarah is the Associate Director of Quality for Intera.  She has extensive experience with medical device startups, working from small single-digit employee projects to larger companies, and in implantables, home health care devices, laboratory equipment, and biologics among others.  She has experience in all areas of medical device quality assurance and quality control.  Prior to coming to Intera, she worked for Tepha Inc, primarily working on Supplier and Quality Control.  Sarah holds an MBA from Georgia State University, as well as a Masters in Biomedical Engineering, and a Bachelors from Georgia Institute of Technology.
Zachary Lappen

Zachary Lappen

Associate Director of Technical Operations

Zachary Lappen leads Intera Oncology’s engineering, operations, and supply chain management activities. He has extensive experience in medical device research and development, product management, and project management. Before joining Intera, Zachary managed projects at CSA Medical bringing the next generation RejuvenAir product to pivotal phase clinical trial and preparing new product launch of a new line of truFreeze catheters. At Infinera, Zachary oversaw supplier quality, inventory management, and change control for flagship product line. Zachary graduated from Lafayette College with a Bachelor’s of Science in Mechanical Engineering and is currently pursuing an MBA at Boston University Questrom School of Business.



David Dove

David Dove, MD MBA


Dr. Dove has extensive experience in healthcare and leading development stage life science companies. In addition to his role as Chairman of Intera, Dr. Dove also serves on the boards of Serpin Pharma and Atacama Therapeutics. Previously, Dr. Dove was President and CEO of Aeris Therapeutics, which developed and commercialized a treatment for patients with advanced emphysema. Dr. Dove also served as President and CEO of Celadon Science (aka Advanced BioHealing), a biotechnology company focused on skin and wound healing, and as President and CEO of TEI Biosciences, a regenerative medicine company. Dr. Dove received an M.D. degree from New York University and an MBA from the Haas School of Business at Berkeley.
Jonathan Reis

Jonathan Reis, MD MBA


President & CEO of Censa Pharmaceuticals. Over 25 years of executive management in the life science industry, President of Cardioresponse, VP Coordinated Care Solutions, Managing Partner of Extera, Managing Director & Head Life Sciences at Armory Securities, Board Member of Janus Biotherapeutics, Atacama Therapeutics & Acer Therapeutics, and multiple corporate development roles with small to midsize life science companies. Jonathan earned his MD from Technion Institute of Technology and his MBA from Harvard Business School.
Joseph Baron

Joseph Baron, MBA


Joseph has extensive experience in the pharmaceutical industry as CEO of Janus Biotherapeutics, CEO of Atacama Therapeutics, Partner at Extera Partners, SVP of Corporate Development at BioAssets, member of the M&A Team at Millennium Pharmaceuticals, and Consultant for Booz Allen.
© Copyright 2021 Intera Oncology. All Right Reserved Designed by Medtech Momentum